Here's why the Botanix (ASX:BOT) share price is slipping today

Botanix was busy over the fourth quarter, but its accomplishments aren't being well received by the market.

| More on:
Man slipping over on banana skin

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Botanix Pharmaceuticals Ltd (ASX: BOT) share price is dipping after the company released its latest quarterly report.

The cannabinoid-focused pharmaceutical dermatology company's quarter seemed to be a good one, but the market has reacted poorly.

Right now, the Botanix share price is 7.8 cents – 3.7% lower than its previous close.

Let's take a closer look at today's news from Botanix.

The news driving the Botanix share price

The Botanix share price is sliding despite the company's productive quarter that ended on 30 June. Let's take a look at what it was up to over the period.

Financial update

Botanix provided a brief financial update on its performance this quarter.  

The company stated it had $21.6 million in cash at the end of the quarter. That's enough to fund an estimated 12.8 future quarters.

During the quarter, it had net cash outflows of around $1.7 million and it invested roughly $1.2 million in research and development activities.

New drugs

The Botanix share price is dipping despite plenty of productivity over the 3 months ended 30 June.

Botanix launched the Phase 1B rosacea clinical study trial for its BTX 1702 product in June.

The trial is investigating the safety and tolerability of different concentrations of BTX 1702 over an 8-week period.

It's currently being hampered by COVID-19 restrictions. The company's looking at adding more trial sites to minimise the impact of potential future lockdowns.

Additionally, Botanix announced positive results from its BTX 1204A pilot study in canines with atopic dermatitis during the quarter.

The company said atopic dermatitis in canines is similar to that in humans and that the study's results are a good indication the treatment could be transferable.

Also, during the quarter Botanix launched the next phase of its BTX 1801 development program.

The program is aiming to help the nasal decolonisation of Staphylococcus aureus in haemodialysis patients.

It hopes BTX 1801 will help to prevent bloodstream infections in those undergoing haemodialysis, of which the company says there's an "urgent need and significant market opportunity".

Botanix Pharmaceuticals share price snapshot

The Botanix share price hasn't been having a great year so far on the ASX.

It is currently 39% lower than it was at the start of 2021. However, it has gained 58% since this time last year.

The company has a market capitalisation of around $78 million, with approximately 973 million shares outstanding.

Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

ASX share price movement represented by doctor pressing digitised screen with array of icons including one entitled health insurance,
Healthcare Shares

Here's why ASX 200 health insurance shares like Medibank are being trounced today

Investors are feeling a bit sick after the latest update.

Read more »

Three Archer Materials scientists wearing white coats and blue gloves dance together in their lab after making a discovery
Record Highs

Superstar ASX 200 healthcare stock snags record high amid $32 million deal

The second multi-million-dollar deal in less than two weeks.

Read more »

Two happy pharmacists standing together in a pharmacy.
Healthcare Shares

Here's why a leading fund manager is excited by this ASX healthcare share

WAM thinks this stock is capable of producing good returns.

Read more »

A medical specialist holds a red heart connected via technology and artificial intelligence (AI)
Share Gainers

Guess which ASX biotech stock just rocketed 25% on big US news

Here are all the details.

Read more »

A woman reclines in a comfortable chair while she donates blood holding a pumping toy in one hand and giving the thumbs up in the other as she is attached to a medical machine to collect her blood donation.
Healthcare Shares

Fundie bullish on CSL shares after praising the 'special business'

Earnings growth justifies current valuations, these experts say.

Read more »

Shot of a young scientist using a digital tablet while working in a lab.
Healthcare Shares

Guess which ASX 200 healthcare stock is charging higher following FDA update

What is getting investors excited today? Let's find out.

Read more »

Two happy scientists analysing test results.
52-Week Highs

3 ASX All Ords health care shares that reached 52-week peaks today

These health care companies finished the week on a positive note.

Read more »

a doctor in a white coat makes a heart shape with his hands and holds it over his chest where his heart is placed.
Healthcare Shares

2 ASX healthcare shares rocketing over 16% on Big US news

These companies are making their shareholders smile on Thursday. But why?

Read more »